InMed presents Phase 2 clinical study results at 12th World Congress on Itch
At the 12th World Congress on Itch (WCI), held in Miami on November 5-7, 2023, InMed’s Senior VP, Clinical and Regulatory Affairs, Alexandra Mancini presented
At the 12th World Congress on Itch (WCI), held in Miami on November 5-7, 2023, InMed’s Senior VP, Clinical and Regulatory Affairs, Alexandra Mancini presented
InMed’s INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Promising early studies demonstrate INM-901’s neuroprotective effects and an ability
Jerry Griffin, VP of Sales and Marketing at BayMedica, InMed’s subsidiary, joins this live panel discussion “Transforming the CPG Landscape: Why Rare Cannabinoids Ingredients are
© Copyright 2024 InMed Pharmaceuticals Inc.
"*" indicates required fields